anti-claudin18.2/anti-cd3 bispecific antibody azd5863
Generic: Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863
anti-claudin18.2/anti-cd3 bispecific antibody azd5863: 1 clinical trial tracked.
anti-claudin18.2/anti-cd3 bispecific antibody azd5863 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-claudin18.2/anti-cd3 bispecific antibody azd5863, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors
Primary endpoint: The number of patients with adverse events
InterventionalRandomizedopen280 targetStarted 2023-07Completion 2027-0725 sites · China, France, Japan, Netherlands…AstraZeneca